Bristol-Myers Squibb (NYSE:BMY) Shares Bought by ORG Partners LLC

ORG Partners LLC lifted its position in Bristol-Myers Squibb (NYSE:BMY) by 785.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,464 shares of the biopharmaceutical company’s stock after acquiring an additional 10,170 shares during the quarter. ORG Partners LLC’s holdings in Bristol-Myers Squibb were worth $473,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Riverview Trust Co grew its position in shares of Bristol-Myers Squibb by 42.7% in the 2nd quarter. Riverview Trust Co now owns 4,636 shares of the biopharmaceutical company’s stock worth $193,000 after acquiring an additional 1,388 shares in the last quarter. Jackson Grant Investment Advisers Inc. boosted its position in Bristol-Myers Squibb by 4.7% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 6,086 shares of the biopharmaceutical company’s stock valued at $253,000 after purchasing an additional 271 shares during the period. Burke & Herbert Bank & Trust Co. boosted its position in Bristol-Myers Squibb by 214.1% during the 2nd quarter. Burke & Herbert Bank & Trust Co. now owns 15,264 shares of the biopharmaceutical company’s stock valued at $634,000 after purchasing an additional 10,405 shares during the period. M&G Plc boosted its position in Bristol-Myers Squibb by 34.1% during the 2nd quarter. M&G Plc now owns 9,751,027 shares of the biopharmaceutical company’s stock valued at $409,543,000 after purchasing an additional 2,480,515 shares during the period. Finally, WASHINGTON TRUST Co boosted its position in Bristol-Myers Squibb by 2.0% during the 2nd quarter. WASHINGTON TRUST Co now owns 15,484 shares of the biopharmaceutical company’s stock valued at $643,000 after purchasing an additional 304 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 1.1 %

Shares of Bristol-Myers Squibb stock traded up $0.53 on Thursday, reaching $48.94. 4,340,490 shares of the company were exchanged, compared to its average volume of 15,857,218. The stock has a fifty day moving average price of $43.42 and a 200-day moving average price of $46.59. The firm has a market capitalization of $99.21 billion, a price-to-earnings ratio of -15.62, a price-to-earnings-growth ratio of 12.51 and a beta of 0.44. The company has a current ratio of 1.16, a quick ratio of 0.99 and a debt-to-equity ratio of 2.86. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.41.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business had revenue of $12.20 billion for the quarter, compared to the consensus estimate of $11.54 billion. During the same quarter in the previous year, the company posted $1.75 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 8.7% compared to the same quarter last year. On average, analysts expect that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were issued a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.90%. Bristol-Myers Squibb’s dividend payout ratio is -77.42%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. BMO Capital Markets reduced their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. Deutsche Bank Aktiengesellschaft reduced their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. TD Cowen boosted their price target on Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a research report on Monday. Finally, Wells Fargo & Company boosted their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $54.86.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.